<DOC>
	<DOCNO>NCT00368615</DOCNO>
	<brief_summary>The aim study study T-cells . Blood collect sample use generate T cell clone . Two separate blood draw require maximum .</brief_summary>
	<brief_title>Characterization Melanoma-Specific Immune Response</brief_title>
	<detailed_description>The aim study in-vitro characterize expand T cell specific melanoma-derived antigen . Peripheral blood collect 20 volunteer biopsy proven melanoma 10 age match control . Blood collect prior initiation chemotherapy . There two blood draw per patient . Most patient receive single blood draw ; however , participant may ask return single additional blood draw investigator unable isolate melanoma-specific immune cell first blood draw . Two separate blood draw maximum . The interval blood draw minimum 3 month apart . Blood sample use determine patient 's HLA haplotype via PCR DNA sequencing . After patient 's haplotype establish melanoma-specific T cell clone generate peripheral blood sample expand in-vitro . These clone assay specificity commercially available melanoma cell line . The T cell clone also assay reactivity melanocyte differentiation antigens MART-1 gp100 . If volunteer require palliative resection melanoma tumor patient 's tumor cell may also use test specificity isolate T cell clone . All experiment conduct in-vitro .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Biopsy diagnosis malignant melanoma Have biopsy diagnosis malignant melanoma past Patients take immunosuppressive medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>melanoma</keyword>
	<keyword>malignant melanoma</keyword>
</DOC>